Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.
结果本例患者临床症状既明显胸
,也
与
胀,而以进行性加重的呼吸困难为表
。
Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.
结果本例患者临床症状既明显胸
,也
与
胀,而以进行性加重的呼吸困难为表
。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发问题,欢迎向我们指正。
Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.
结果本例患者临床症状既无明显,
无腹
与腹胀,而以进行性加重的呼吸困难为表
。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发问题,欢迎向我们指正。
Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.
结果本患者临床症状既无
显胸痛,也无腹痛与腹胀,而
进行性加重的呼吸困难为表
。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
:
上
、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发
问题,欢迎向我们指正。
Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.
结果本例患者临床症状既无明显胸痛,也无腹痛与腹胀,而以进行性加重的呼吸困难为表。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动,
分未经过人工审核,其表达内容亦不代表本软件的观点;若发
问题,欢迎向我们指正。
Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.
结果本例患者临床无明显胸痛,也无腹痛与腹胀,而以进行性加重的呼吸困难为表
。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并硬化的慢性丙
(CHC)患者接受α干扰素包括派罗欣治疗时存
能失代偿和死亡风险。
声明:以上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发问题,欢迎向我们指正。
Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.
结果本例患者临床症状既无明显胸痛,也无腹痛与腹胀,而以进行性加重的呼吸困难为表。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代和死亡风险。
声明:以上例句、词性分类联网资源自动生成,部分未经过人工审核,其表达内容亦
代表本软件的观点;若发
问题,欢迎向我们指正。
Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.
结果本例患者临床症状既无明显胸痛,也无腹痛与腹,
进行性加重的呼吸困难为表
。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者α
扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:上例句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发
问题,欢迎向我们指正。
Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.
结果本患者临床症状既无明显胸痛,也无腹痛与腹胀,而
进行性加重的呼吸困难为表
。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:句、词性分类均由互联网资源自动生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发
问题,欢迎向我们指正。
Results Clinical symptom of the case in the report was progressively deteriorating in decompensation but without obvious chest pain,bellyache,or burbulence.
结果本患者临床症状既无明显胸痛,也无腹痛与腹胀,而以进行性加重的呼吸困难为表
。
Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.
合并肝硬化的慢性丙肝(CHC)患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。
声明:以、词性分类均由互联网资源自
生成,部分未经过人工审核,其表达内容亦不代表本软件的观点;若发
问题,欢迎向我们指正。